Literature DB >> 9328494

Prospective longitudinal study of depression and anosognosia in Alzheimer's disease.

S E Starkstein1, E Chemerinski, L Sabe, G Kuzis, G Petracca, A Tesón, R Leiguarda.   

Abstract

BACKGROUND: The aim was to examine the longitudinal evolution of depression and anosognosia in patients with probable Alzheimer's disease (AD).
METHOD: Sixty-two of a consecutive series of 116 AD patients that were examined with a structured psychiatric interview had a follow-up evaluation between one and two years after the initial evaluation.
RESULTS: At the initial evaluation 19% of the 62 patients had major depression, 34% had dysthymia, and 47% were not depressed. After a mean follow-up of 16 months, 58% of patients with major depression at the initial evaluation were still depressed, whereas only 28% of patients with initial dysthymia and 21% of the non-depressed patients were depressed at follow-up. During the follow-up period, all three groups showed similar declines in cognitive status and activities of daily living. At the initial evaluation, 39% of the patients had anosognosia, and there was a significant increment of anosognosia during the follow-up period.
CONCLUSIONS: While dysthymia in AD is a brief emotional disorder, major depression is a longer-lasting mood change. Anosognosia is another prevalent disorder among AD patients, and increases with the progression of the illness.

Entities:  

Mesh:

Year:  1997        PMID: 9328494     DOI: 10.1192/bjp.171.1.47

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  27 in total

Review 1.  Neuropsychiatric aspects of Alzheimer's disease.

Authors:  C Ballard; M Walker
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Right prosubiculum amyloid plaque density correlates with anosognosia in Alzheimer's disease.

Authors:  G A Marshall; D I Kaufer; O L Lopez; G R Rao; R L Hamilton; S T DeKosky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 3.  Anosognosia in Dementia.

Authors:  Robert S Wilson; Joel Sytsma; Lisa L Barnes; Patricia A Boyle
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

4.  Neuropsychological function in nondemented carriers of presenilin-1 mutations.

Authors:  J M Ringman; C Diaz-Olavarrieta; Y Rodriguez; M Chavez; L Fairbanks; F Paz; A Varpetian; H C Maldonado; M A Macias-Islas; J Murrell; B Ghetti; C Kawas
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

5.  Temporal course and pathologic basis of unawareness of memory loss in dementia.

Authors:  Robert S Wilson; Patricia A Boyle; Lei Yu; Lisa L Barnes; Joel Sytsma; Aron S Buchman; David A Bennett; Julie A Schneider
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

6.  Neural correlates of anosognosia for cognitive impairment in Alzheimer's disease.

Authors:  Eric Salmon; Daniela Perani; Karl Herholz; Patricia Marique; Elke Kalbe; Vjera Holthoff; Xavier Delbeuck; Bettina Beuthien-Baumann; Oriana Pelati; Solange Lespagnard; Fabienne Collette; Gaëtan Garraux
Journal:  Hum Brain Mapp       Date:  2006-07       Impact factor: 5.038

Review 7.  Unawareness of deficits in Alzheimer's disease and other dementias: operational definitions and empirical findings.

Authors:  Eric Ecklund-Johnson; Ivan Torres
Journal:  Neuropsychol Rev       Date:  2005-09       Impact factor: 7.444

8.  A diagnostic formulation for anosognosia in Alzheimer's disease.

Authors:  S E Starkstein; R Jorge; R Mizrahi; R G Robinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-20       Impact factor: 10.154

9.  Prevalence of Depression, Anxiety and PTSD in People with Dementia: a Systematic Review and Meta-Analysis.

Authors:  J K Kuring; J L Mathias; L Ward
Journal:  Neuropsychol Rev       Date:  2018-12-07       Impact factor: 7.444

Review 10.  Disorders of awareness in neuropsychiatric syndromes: an update.

Authors:  Laura A Flashman
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.